Method for treating neuroendocrine tumors

CD47-SIRPa pathway inhibitors like evorpacept and magrolimab offer a promising treatment for neuroendocrine tumors by suppressing tumor activity and secretory functions, addressing the limitations of current therapies.

WO2026234716A1PCT designated stage Publication Date: 2026-11-12AURIGENE ONCOLOGY LIMITED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IN2026/050798
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for neuroendocrine tumors (NETs) are limited, with chemotherapy having little efficacy and existing targeted therapies showing low response rates and severe side effects, making them difficult to treat, especially when metastasized.

Method used

Administering a therapeutically effective amount of a CD47-SIRPa pathway inhibitor, such as evorpacept, letaplimab, or magrolimab, to suppress the secretory activity of neuroendocrine tumors.

Benefits of technology

The CD47-SIRPa pathway inhibitors effectively reduce tumor growth and secretory activity, providing a therapeutic benefit with reduced side effects compared to existing treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IN2026050798_12112026_PF_FP_ABST
    Figure IN2026050798_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to a method for treating neuroendocrine tumors in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a CD47-SIRPα pathway inhibitor. The CD47-SIRPα pathway inhibitor is selected 5 from the group of small molecules or anti-CD47 antibodies.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] METHOD FOR TREATING NEUROENDOCRINE TUMORS RELATED APPLICATION

[0002] This application claims the benefit of the Indian provisional patent application number 202541044601, filed on May 08, 2025; the contents of which is hereby incorporated by reference in its entirety.

[0003] FIELD

[0004] The present disclosure relates to a method for treating neuroendocrine tumors (NETs). More particularly, it relates to a method for treating neuroendocrine tumors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a CD47-SIRPa pathway inhibitor.

[0005] BACKGROUND

[0006] Neuroendocrine tumors are uncommon tumors that arise from neuroendocrine cells, which are widely dispersed throughout the body. Neuroendocrine tumors are generally slow growing (Sultana Q et al., A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management. J Clin Med. 2023 Aug 5; 12(15):5138).

[0007] Most patients with NETs have mild symptoms at presentation, and their tumors may be diagnosed only upon examinations or radiological scans or endoscopies. Although functional NETs that produce certain hormones and other chemicals often cause patients to exhibit symptoms, the non-specific nature of these symptoms can lead to delayed diagnosis or even a misdiagnosis. By the time patients with NETs are correctly diagnosed, the cancer has usually metastasized, with regional or distant metastasis observed in approximately 50% of cases (Raphael MJ et al., Principles of diagnosis and management of neuroendocrine tumours. CMAJ. 2017 Mar 13; 189(10): E398-E404). With the potential to spread, NETs can be lifethreatening and difficult to treat with currently available treatments. Once NETs have metastasized, they generally are not curable and cannot be effectively treated by surgery alone. Moreover, there are limited number of options currently available for the treatment of advanced NETs. Chemotherapy and limited targeted therapies have been approved for pancreatic NET (pNET), gastro-intestinal NET and pulmonary NET. Many patients exhaust all the available treatments (Herrera-Martinez AD et al., Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs. 2019 Jan;79(l):21-42).While chemotherapeutic agents and some targeted therapies have become the standard of care treatments for NETs, the response rates with the two approved drugs (everolimus and sunitinib) are less than 10%. Both these agents have shown limited overall survival benefit, though the pivotal trials showed PFS (Progression Free Survival) benefits. (Karpathakis A et al., Hitting the target: where do molecularly targeted therapies fit in the treatment scheduling of neuroendocrine tumours? Endocrine-Related Cancer, 2012; 19(3), R73-R92).

[0008] Afinitor® (everolimus), a mammalian target of the rapamycin (imTOR) inhibitor, can cause severe skin and gastrointestinal disorders, kidney and liver toxicity and bone marrow damage (Coppin C. Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and / or sorafenib. Biologies. 2010 May 25; 4:91-101).

[0009] Sutent® (sunitinib), a multi-targeted receptor tyrosine kinase (RTK) inhibitor approved for the treatment of unresectable or metastatic, well-differentiated pNETs with disease progression in adults, may cause severe side effects such as renal failure, heart failure, gastrointestinal disorders, hemorrhages, neutropenia, thrombocytopenia, and anemia which are among its most common adverse drug reactions (Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs. 2009; 23(6):377-89).

[0010] Traditional chemotherapy has little place in the treatment of well-differentiated NETs, since most of these tumors are slow growing. The risks of chemotherapy, with respect to their side effects, outweigh the potential benefits.

[0011] OBJECTIVE

[0012] An objective of the present disclosure is to provide a method for treating neuroendocrine tumors in a subject. More particularly, the disclosure relates to a method of treatment of neuroendocrine tumors using a CD47 SIRP-alpha inhibitor.

[0013] SUMMARY

[0014] The disclosure herein provides a method for treating neuroendocrine tumors, using a CD47-SIRPa pathway inhibitor.In one aspect, the disclosure herein provides a method for treating neuroendocrine tumor (NET) in a subject in need thereof, the method comprising administering to the subject, a therapeutically effective amount of a CD47-SIRPa pathway inhibitor.

[0015] In one embodiment, the CD47-SIRPa pathway inhibitor is selected from the group consisting of small molecules and anti-CD47 antibodies.

[0016] In one embodiment, the CD47-SIRPa pathway inhibitor is selected from the group consisting of a small molecule and an anti-CD47 antibody.

[0017] In one embodiment, the anti-CD47 antibody is selected from the group consisting of polyclonal antibodies, recombinant antibodies, monoclonal antibodies, antibody fragments, single chain variable fragments (scFv’s), chimeric antibodies, humanized antibodies and fusion proteins.

[0018] In one embodiment, the anti-CD47 antibody is selected from the group consisting of a polyclonal antibody, a recombinant antibody, a monoclonal antibody, an antibody fragment, a single-chain variable fragment (scFv), a chimeric antibody, a humanized antibody, and a fusion protein.

[0019] In one embodiment, the CD47-SIRPa pathway inhibitor is selected from the group consisting of evorpacept, ligufalimab, letaplimab, lemzoparlimab, magrolimab, maplirpacept, simridarlimab, ISM-8207, TQB-2928, XL-114, IMC-002, STI-6643, HMPE-A83, DS-1103, SG-2501, IMM-02, IMM-4002, IMM-6101, CO-005, IMD-1005, AETA-002, CC-90002, MP 0621, VT-1021, AO-176, DSP-107, JMT-601, TTI-621, IMM-2902, ISB-1442, HX-009, 6MW-3211, SG-404, GenSci-05, SHR-1603, MIL-95, NI-1801, SG-1906, AK-132, IMM-2520, SG-12473, SHS-009, BAT-7104, QL-401, D3L-001, BC-007, TG-1801, AVI-105, KD-015, SCR-9168, HX-015, GB-7005, FP-002, SY-102, LP-007, DS-003, LQ-001, SBI-102, KBI-436, TRB-805-01, IMM-5601 and SC-2882.

[0020] In one embodiment, the CD47-SIRPa pathway inhibitor is selected from the group consisting of evorpacept, letaplimab, magrolimab, ISM-8207, TQB-2928, XL-114, IMC-002, STI-6643, HMPL-A83, DS-1103, SG-2501, IMM-02, IMM-4002, IMM-6101, CO-005, IMD-1005, ALTA-002, CC-90002, MP 0621 and SC-2882.

[0021] In one embodiment, the CD47-SIRPa pathway inhibitor is selected from the group consisting of evorpacept, letaplimab, magrolimab and STI-6643.In one embodiment, the CD47-SIRPa pathway inhibitor is a compound represented by formula (I):

[0022]

[0023] (I)

[0024] or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof. In another aspect, the disclosure herein provides a method for suppressing secretory activity of a neuroendocrine tumor, using a CD47-SIRPa pathway inhibitor.

[0025] In another aspect, the disclosure herein provides a method for suppressing secretory activity of a neuroendocrine tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a CD47-SIRPa pathway inhibitor.

[0026] In another aspect, the disclosure herein provides the use of a CD47-SIRPa pathway inhibitor in the manufacture of a medicament for treating neuroendocrine tumors in a subject.

[0027] In another aspect, the disclosure herein provides a CD47-SIRPa pathway inhibitor for use in a method for treating neuroendocrine tumors in a subject in need thereof.

[0028] In one aspect, the present disclosure provides a pharmaceutical composition comprising the compound of formula (I), or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof and one or more pharmaceutically acceptable excipients, for the treatment of neuroendocrine tumors.

[0029] In one aspect, the present disclosure provides a calcium salt of compound of formula (I), for the treatment of neuroendocrine tumors.

[0030] In one aspect, the present disclosure provides a pharmaceutical composition comprising the compound of formula (I), or the calcium salt of compound of formula (I) and one or more pharmaceutically acceptable excipients, for the treatment of neuroendocrine tumors.In one aspect, the present disclosure provides a tablet composition comprising the compound of formula (I) or the calcium salt of compound of formula (I) in accordance with the present disclosure.

[0031] In one aspect, the present disclosure provides a method of treating neuroendocrine tumors comprising administering a therapeutically effective amount of the compound of formula (I) or the calcium salt of compound of formula (I), or a pharmaceutical composition comprising the compound of formula (I) or the calcium salt of compound of formula (I) to a patient in need thereof.

[0032] In one aspect, the present disclosure provides a use of the compound of formula (I) or the calcium salt of compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) or the calcium salt of compound of formula (I) according to the disclosure, in the manufacture of a medicament for treatment of neuroendocrine tumors.

[0033] BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 provides CT scan image of abdominal lesion in peritoneum before (baseline) and after (at cycle 6) the administration of the test compound (compound of formula (I)).

[0035] Figure 2 provides CT scan image of metastatic lesion in left lobe of liver before (baseline) and after (at cycle 6) the administration of the test compound (compound of formula (I)).

[0036] Figure 3 provides the PET-CT scan image of the second metastatic lesion in left lobe of liver before (baseline) and after (at Cycle 6) the administration of the test compound (compound of formula (I)).

[0037] DETAILED DESCRIPTION

[0038] As used herein the term ‘NET’ covers a rare, slow-growing form of tumor that arises from neuroendocrine cells. NETs as a whole are a heterogeneous group of neoplasms whose characteristics can vary depending upon the tissue of origin. NETs originate from a wide variety of organs such as the pancreas, gastrointestinal tract and respiratory tract. The most common location of gastrointestinal NETs includes the stomach, small intestine, ileum, colon and rectum. In certain embodiments, NETs may also be referred to as “carcinoid tumors” which generally refer to NETs originating from the diffuse neuroendocrine system.The disclosure herein provides a method for treating neuroendocrine tumors, using a CD47-SIRPa pathway inhibitor.

[0039] In one embodiment, the disclosure herein provides a method for treating neuroendocrine tumors in a subject in need thereof, the method comprising administering to the subject, a therapeutically effective amount of a CD47-SIRPa pathway inhibitor.

[0040] According to the present disclosure, the CD47-SIRPa pathway inhibitor is selected from the group consisting of small molecules and anti-CD47 antibodies.

[0041] According to the present disclosure, the anti-CD47 antibody is selected from the group consisting of polyclonal antibodies, recombinant antibodies, monoclonal antibodies, antibody fragments, scFv’s, chimeric antibodies, humanized antibodies and fusion proteins.

[0042] In certain embodiments, the CD47-SIRPa pathway inhibitor is selected from the group consisting of evorpacept, ligufalimab, letaplimab, lemzoparlimab, magrolimab, maplirpacept, simridarlimab, ISM-8207, TQB-2928, XL-114, IMC-002, STI-6643, HMPL-A83, DS-1103, SG-2501, IMM-02, IMM-4002, IMM-6101, CO-005, IMD-1005, ALTA-002, CC-90002, MP 0621, VT-1021, AO-176, DSP-107, JMT-601, TTI-621, IMM-2902, ISB-1442, HX-009, 6MW-3211, SG-404, GenSci-05, SHR-1603, MIL-95, NI-1801, SG-1906, AK-132, IMM-2520, SG-12473, SHS-009, BAT-7104, QL-401, D3L-001, BC-007, TG-1801, AVI-105, KD-015, SCR-9168, HX-015, GB-7005, FP-002, SY-102, LP-007, DS-003, LQ-001, SBI-102, KBI-436, TRB-805-01, IMM-5601 and SC-2882.

[0043] In certain embodiments, the CD47-SIRPa pathway inhibitor is selected from the group consisting of evorpacept, letaplimab, magrolimab, ISM-8207, TQB-2928, XL-114, IMC-002, STI-6643, HMPL-A83, DS-1103, SG-2501, IMM-02, IMM-4002, IMM-6101, CO-005, IMD-1005, ALTA-002, CC-90002, MP 0621 and SC-2882.

[0044] In one embodiment, the CD47-SIRPa pathway inhibitor is selected from the group consisting of evorpacept, letaplimab, magrolimab and STI-6643.

[0045] In preferred embodiments, the CD47-SIRPa pathway inhibitor is a compound represented by formula (I):

[0046]

[0047] or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof.

[0048] In one embodiment, the CD47-SIRPa pathway inhibitor is a calcium salt of compound represented by formula (I).

[0049] NETs are histologically classified according to tumor differentiation and tumor grade. Histologically, it can be classified according to the degree of tumor differentiation (well differentiated, poorly differentiated) and tumor grade (low grade, medium grade or high-grade). Tumor differentiation and tumor grade are often associated with mitotic counts and Ki-67 proliferation indices. Many studies have demonstrated that high mitotic rates and high Ki-67 indices correlate with greater aggressiveness and poor prognosis in NETs.

[0050] In one embodiment, classification of neuroendocrine tumors is as per WHO classification. In one embodiment, neuroendocrine tumors in accordance with WHO classification as low grade, medium grade, high-grade, poorly differentiated neuroendocrine tumor, well-differentiated, functional or non- functional neuroendocrine tumor.

[0051] In one embodiment, the neuroendocrine tumor to be treated is a low grade, medium grade or high-grade neuroendocrine tumor.

[0052] In one embodiment, low grade tumors are characterized by <2 mitoses per 10 HPF (high power fields) and no necrosis. In one embodiment, intermediate grade tumors are characterized by 2-10 mitoses per 10 HPF (high power fields) or foci of necrosis. In one embodiment, highgrade tumors are characterized by >10 mitoses per 10 HPF (high power fields).

[0053] In one embodiment, high-grade tumors are characterized by >20 mitoses per 10 HPF (high power fields).

[0054] In another embodiment, low grade tumors are characterized by Ki67 index of < 3%. In one embodiment, intermediate grade tumors are characterized by Ki67 index between 3 - 20%.

[0055] In one embodiment, high-grade tumors are characterized by Ki67 index of > 20%.In one embodiment, the neuroendocrine tumor is a poorly differentiated neuroendocrine tumor or a well-differentiated neuroendocrine tumor.

[0056] In one embodiment, the neuroendocrine tumor is a functional neuroendocrine tumor or a non-functional neuroendocrine tumor.

[0057] In one embodiment, neuroendocrine tumor is considered functional when a specific clinical syndrome is induced due to excessive production of hormones by the tumor cells. In another embodiment, non-functional neuroendocrine tumor is not associated with a clinical syndrome due to excessive production of hormones by the tumor cells, but can still produce symptoms related to the presence of the tumor or its metastasis.

[0058] In one embodiment, the neuroendocrine tumor is an advanced or metastatic neuroendocrine tumor or a combination thereof.

[0059] In one embodiment, the neuroendocrine tumor is selected from the group consisting of lung neuroendocrine tumor, bronchial neuroendocrine tumor, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumors, gastroenteropancreatic neuroendocrine tumor, small intestine neuroendocrine tumor, large intestine neuroendocrine tumor, rectal neuroendocrine tumor, appendix neuroendocrine tumor, duodenal-jejunal neuroendocrine tumor, ovarian neuroendocrine tumor, pheochromocytomas, paragangliomas, medullary thyroid cancer, metastatic neuroendocrine tumor, thymic neuroendocrine tumor, pituitary neuroendocrine tumor, Merkel-cell carcinoma, Ewing's sarcoma, rectal neuroendocrine tumors, duodenal neuroendocrine tumor, jejunal neuroendocrine tumor, neuroendocrine tumor of the ileum and neuroblastoma or any combination thereof.

[0060] In one embodiment, the neuroendocrine tumor is selected from the group consisting of lung neuroendocrine tumor, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumor, duodenal-jejunal neuroendocrine tumor and gastroenteropancreatic neuroendocrine tumor or any combination thereof.

[0061] In one embodiment, the neuroendocrine tumor is duodenal-jejunal neuroendocrine tumor.

[0062] In one embodiment, the subject is a human. In one embodiment, the subject is a human suffering from and / or has been diagnosed with any of the afore defined types of neuroendocrine tumors.In certain embodiments, the subject receives at least one additional form of therapy. In another embodiments, the subject receives at least one additional form of therapy and / or the method comprises subjecting the subject to at least one additional form of therapy.

[0063] According to the present disclosure, the additional form of therapy is selected from surgery, combination therapy, chemotherapy and radiation therapy.

[0064] In one embodiment, the combination therapy comprises administering one or more additional therapeutic agents.

[0065] In one embodiment, the combination therapy comprises administering a CD47-SIRPa pathway inhibitor and one or more additional therapeutic agents.

[0066] In one embodiment, the combination therapy comprises administering a CD47-SIRPa pathway inhibitor and one or more additional therapeutic agents sequentially.

[0067] In one embodiment, the combination therapy comprises administering a CD47-SIRPa pathway inhibitor and one or more additional therapeutic agents simultaneously.

[0068] In one embodiment, the combination therapy comprises co-administering a CD47-SIRPa pathway inhibitor and one or more additional therapeutic agents.

[0069] In one embodiment, the CD47-SIRPa pathway inhibitor is administered before one or more additional therapeutic agents.

[0070] In one embodiment, the CD47-SIRPa pathway inhibitor is administered after one or more additional therapeutic agents.

[0071] In one embodiment, the combination therapy comprises administering CD47-SIRPa pathway inhibitor and one or more additional therapeutic agents selected from the group consisting of everolimus, sunitinib, cabozantinib and somatostatin analogs.

[0072] In one embodiment, the combination therapy comprises administering a CD47-SIRPa pathway inhibitor and everolimus.

[0073] In one embodiment, the combination therapy comprises administering a CD47-SIRPa pathway inhibitor and sunitinib.

[0074] In one embodiment, the combination therapy comprises administering a CD47-SIRPa pathway inhibitor and cabozantinib.In one embodiment, the combination therapy comprises administering a CD47-SIRPa pathway inhibitor and one or more somatostatin analogs.

[0075] In one embodiment, the method further comprising administering to the subject, a therapeutically effective amount of an additional therapeutic agent.

[0076] In some embodiment, the additional therapeutic agent includes but does not limit to everolimus, sunitinib, cabozantinib and somatostatin analogs.

[0077] In some embodiment, the additional therapeutic agent is selected from the group of everolimus, sunitinib, cabozantinib and somatostatin analogs.

[0078] In some embodiment, the additional therapeutic agent is selected from the group of everolimus, sunitinib, cabozantinib.

[0079] The disclosure herein provides a combination comprising a CD47-SIRPa pathway inhibitor and one or more additional therapeutic agents.

[0080] In one embodiment, the combination comprising a CD47-SIRPa pathway inhibitor and one or more additional therapeutic agents for treating neuroendocrine tumors is disclosed herein.

[0081] In one embodiment, the combination comprising a CD47-SIRPa pathway inhibitor represented by formula (I):

[0082]

[0083] (I)

[0084] or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof and one or more other therapeutic agents for treating neuroendocrine tumors is disclosed herein.

[0085] In one embodiment, additional therapeutic agents are selected from a group consisting of sunitinib, everolimus, cabozantinib and somatostatin analogs.

[0086] In one embodiment, additional therapeutic agents are selected from a group consisting of sunitinib, everolimus and cabozantinib.In one embodiment, somatostatin analogs are selected from octreotide and lanreotide. In certain embodiments, the method comprises the step of subjecting the subject to one or more tests for diagnosing a neuroendocrine tumor and / or of diagnosing the subject with a neuroendocrine tumor, prior to initiating and / or during the administration of / treatment with the CD47-SIRPa pathway inhibitor in accordance with the present disclosure.

[0087] In one embodiment, the disclosure herein provides a method for suppressing the secretory activity of a neuroendocrine tumor, using a CD47-SIRPa pathway inhibitor.

[0088] In one embodiment, the disclosure herein provides a method for suppressing the secretory activity of a neuroendocrine tumor in a subject in need thereof, the method comprising administering to the subject, a therapeutically effective amount of a CD47-SIRPa pathway inhibitor.

[0089] In one embodiment, the disclosure herein provides use of a CD47-SIRPa pathway inhibitor in the manufacture of a medicament for treating neuroendocrine tumors in a subject.

[0090] In one embodiment, the disclosure herein provides a CD47-SIRPa pathway inhibitor for use in treating neuroendocrine tumors.

[0091] As will be evident from the foregoing, in one preferred embodiment, the said CD47-SIRPa pathway inhibitor is a compound represented by formula (I):

[0092]

[0093] (I)

[0094] or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof.

[0095] In one particularly preferred embodiment, the disclosure herein provides a compound of formula (I) or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof, for use in treating neuroendocrine tumors in a subject:

[0096]

[0097] In some preferred embodiments, the disclosure herein provides a calcium salt of compound of formula (I) for use in treating a neuroendocrine tumor in a subject:

[0098]

[0099] (I)

[0100] In some preferred embodiments, the disclosure herein provides the use of a CD47- SIRPa pathway inhibitor represented by formula (I) or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof, in the manufacture of a medicament for treating a neuroendocrine tumor in a subject:

[0101]

[0102] In some preferred embodiments, the disclosure herein provides the use of a CD47- SIRPa pathway inhibitor represented by formula (I) or a calcium salt of compound represented by formula (I), in the manufacture of a medicament for treating a neuroendocrine tumor in a subject:

[0103]

[0104] In some embodiments, the disclosure herein provides a pharmaceutical composition comprising a CD47-SIRPa pathway inhibitor represented by formula (I) or a calcium salt of the compound of formula (I) thereof, and one or more pharmaceutically acceptable excipients for treating a neuroendocrine tumor in a subject.

[0105] In some embodiments, the disclosure herein provides, a pharmaceutical composition comprising a compound of formula (I), or a calcium salt thereof, and one or more pharmaceutically acceptable excipients for use in the treatment of neuroendocrine tumor. In one embodiment, the neuroendocrine tumor is selected from the group consisting of lung neuroendocrine tumor, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumor, duodenal-jejunal neuroendocrine tumor and gastroenteropancreatic neuroendocrine tumor or any combination thereof.

[0106] In some embodiments, the pharmaceutical composition in accordance with the disclosure is a solid oral dosage form, preferably selected from tablet, capsule, oral liquid dosage form such as oral liquid solution or oral liquid suspension, powder or powder for oral suspension.

[0107] In some embodiments, the pharmaceutical composition in accordance with the disclosure is a tablet.

[0108] In some embodiments, the present disclosure provides a tablet composition comprising a CD47-SIRPa pathway inhibitor represented by formula (I) or a calcium salt of the compound of formula (I) for treating a neuroendocrine tumor in a subject.

[0109] In some embodiments, the present disclosure provides oral administration of the compound of formula (I) or calcium salt of compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) or calcium salt of compound of formula (I) at a total daily dose not exceeding 800 mg, preferably not exceeding 600 mg, more preferably not exceeding 500 mg, most preferably not exceeding 400 mg to a patient in need thereof for treating a neuroendocrine tumor.In some embodiments, the compound of formula (I) or calcium salt thereof is administered at a total daily dose not exceeding 800 mg, preferably not exceeding 600 mg, more preferably not exceeding 500 mg, most preferably not exceeding 400 mg.

[0110] In some embodiments, the present disclosure provides oral administration of the compound of formula (I) or calcium salt of compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) or calcium salt of compound of formula (I)at a total daily dose of 50 mg to 800 mg to a patient in need thereof for treating a neuroendocrine tumor.

[0111] In some preferred embodiments, the disclosure provides oral administration of the compound of formula (I) or calcium salt of compound of formula (I) or the composition at an amount of 50 mg to 100 mg. In some preferred embodiments, the disclosure provides that the total daily dose of the compound of formula (I) or calcium salt of compound of formula (I) or the composition is 50 mg to 200 mg. In some preferred embodiments, the disclosure provides that the total daily dose of the compound of formula (I) or calcium salt of compound of formula (I) or the composition is 50 mg to 400 mg. In some preferred embodiments, the disclosure provides that the total daily dose of the compound of formula (I) or calcium salt of compound of formula (I) or the composition is 50 mg to 800 mg. In some preferred embodiments, the disclosure provides that the total daily dose of the compound of formula (I) or calcium salt of compound of formula (I) or the composition is 100 mg to 200 mg. In some preferred embodiments, the disclosure provides that the total daily dose of the compound of formula (I) or calcium salt of compound of formula (I) or the composition is 100 mg to 400 mg. In some preferred embodiments, the disclosure provides that the total daily dose of the compound of formula (I) or calcium salt of compound of formula (I) or the composition is 100 mg to 800 mg. In some preferred embodiments, the disclosure provides that the total daily dose of the compound of formula (I) or calcium salt of compound of formula (I) or the composition is 200 mg to 400 mg. In some preferred embodiments, the disclosure provides that the total daily dose of the compound of formula (I) or calcium salt of compound of formula (I) or the composition is 200 mg to 800 mg. In some preferred embodiments, the disclosure provides that the total daily dose of the compound of formula (I) or calcium salt of compound of formula (I) or the composition is 400 mg to 800 mg. In some preferred embodiments, the disclosure provides that the total daily dose of the compound of formula (I) or calcium salt of compound of formula (I) or the composition is 300 mg to 600 mg. In some preferred embodiments, the disclosureprovides that the total daily dose of the compound of formula (I) or calcium salt of compound of formula (I) or the composition is about 600 mg.

[0112] In some embodiments, the disclosure provides oral administration of the compound of formula (I) or calcium salt of compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) or calcium salt of compound of formula (I) at a total daily dose of 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg or 800 mg, to a patient in need thereof for treating a neuroendocrine tumor.

[0113] In some embodiments, the disclosure provides oral administration of formula (I) or calcium salt of compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) or calcium salt of compound of formula (I) once daily or twice daily for at least one cycle of 28 days to a patient in need thereof for treating a neuroendocrine tumor. In some preferred embodiments, the disclosure provides once daily administration in more than one cycles.

[0114] In some embodiments, the present disclosure provides a use of the compound of formula (I) or calcium salt of the compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) or calcium salt of the compound of formula (I) in the manufacture of a medicament for treatment of neuroendocrine tumors.

[0115] In some embodiments, the present disclosure provides a method of treating neuroendocrine tumors in a subject comprising administering to the subject the compound of formula (I) or a calcium salt of compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) or a calcium salt of compound of formula (I) in combination with at least one additional form of therapy selected from surgery, combination therapy, chemotherapy and radiation therapy.

[0116] In some embodiments, the present disclosure provides a method of treating neuroendocrine tumors in a subject comprising administering to the subject the compound of formula (I) or a calcium salt of compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) or a calcium salt of compound of formula (I) in combination with at least one additional form of therapy selected from surgery, somatostatin analogs, Peptide Receptor Radionuclide Therapy (PRRT), targeted therapies, liver-directedtherapies, trans arterial embolisation (TAE), radiofrequency ablation (RFA) and microwave ablation (MWA), immunotherapy, radiation therapy, and chemotherapy.

[0117] In some embodiments, the combination therapy comprises a simultaneous, sequential or a co-administration of the compound of formula (I) or a calcium salt of compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) or a calcium salt of compound of formula (I), and the additional form of therapy selected from surgery, combination therapy, chemotherapy and radiation therapy.

[0118] In some embodiments, the compound of formula (I) or the calcium salt of compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) or the calcium salt of compound of formula (I) is administered before one or more additional form of therapy.

[0119] In some embodiments, the compound of formula (I) or the calcium salt of compound of formula (I) or a pharmaceutical composition comprising the compound of formula (I) or the calcium salt of compound of formula (I) is administered after one or more additional form of therapy.

[0120] In one embodiment, the compound of formula (I) or a calcium salt thereof is administered to the subject via oral route.

[0121] In some embodiments, the compound of formula (I) or a calcium salt thereof is administered to the subject once or twice daily.

[0122] As used herein the terms “subject” or “patient” or “individual”, which may be used interchangeably, mean a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g. , rats, mice, guinea pigs and the like). Preferably, the subject is a human.

[0123] As used herein, the singular forms 'a', 'an' and 'the' include plural referents unless the context clearly dictates otherwise.

[0124] An “effective amount” of the compound of formula (I), or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof, as described herein is an amount sufficient to provide a therapeutic benefit in the treatment of cancer or to delay or minimize or to suppress one or more symptoms associated with the condition. The terms “therapeutically effective amount” and “effective amount” are used interchangeably. The term“effective amount” can encompass an amount that improves overall therapy, reduces or suppresses, or avoids symptoms, signs, or causes of the condition, and / or enhances the therapeutic efficacy of another therapeutic agent. In certain embodiments, an effective amount is an amount sufficient for eliciting therapeutic effects in the treatment of neuroendocrine tumor selected from a lung neuroendocrine tumor, bronchial neuroendocrine tumor, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumors, gastroenteropancreatic neuroendocrine tumor, small intestine neuroendocrine tumor, large intestine neuroendocrine tumor, rectal neuroendocrine tumor, appendix neuroendocrine tumor, duodenal-jejunal neuroendocrine tumor, ovarian neuroendocrine tumor, pheochromocytomas, paragangliomas, medullary thyroid cancer, metastatic neuroendocrine tumor, thymic neuroendocrine tumor, pituitary neuroendocrine tumor, Merkel-cell carcinoma, Ewing's sarcoma, rectal neuroendocrine tumors, duodenal neuroendocrine tumor, jejunal neuroendocrine tumor, neuroendocrine tumor of the ileum and neuroblastoma or any combination thereof. When coadministered with other therapeutic agents, e.g., when co- administered with an anti-cancer agent, an “effective amount” of any additional therapeutic agent(s) will depend on the type of drug used. Suitable dosages are known for approved therapeutic agents and can be adjusted by the skilled artisan according to the condition of the subject, the type of condition(s) being treated and the amount of the compound of formula (I) or pharmaceutically acceptable salt thereof. In cases where no amount is expressly noted, an effective amount should be assumed. Non-limiting examples of an effective amount of CD47-SIRPa inhibitors and the compound of formula (I) or a pharmaceutically acceptable salt thereof are provided herein below.

[0125] An effective amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof is generally in the range from 0.1 pg to 100 mg / kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg / kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as an individual dose per day or usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. The effective dose of the compound of formula (I) or pharmaceutically acceptable salt thereof to a subject is 50 mg to 1000 mg, preferably 100 mg to 800 mg, more preferably 200 mg to 400 mg.

[0126] The term “treat” or “treating” or “treatment” means decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a condition, syndrome, disease / disorder (e.g., neuroendocrine tumor) or lessen the severity of the disease / disorder orinhibiting the progression or worsening of signs and symptoms of a disease, condition, syndrome or disorder in an individual or improve the symptoms associated with the condition, syndrome, disease / disorder. Treatment may also be continued after symptoms have resolved, for example to reduce the likelihood of or delay their recurrence. In accordance with the present disclosure, the methods typically result in any of the following outcomes: suppression of the secretory activity of tumor or lesion, reduced tumor or lesion growth, suppression of tumour or lesion growth, arresting of tumour or lesion growth, stabilization of tumour or lesion size, reduction in tumor / lesion size and / or disappearance of tumor or lesion, as can be established, e.g. with conventional PET-CT imaging techniques, typically applying RECIST criteria. The aforementioned outcomes may relate to the primary tumor / lesion, to a metastatic tumor / lesion or both.

[0127] The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the biological samples and / or tissues of human beings and animals without excessive toxicity, irritation, allergic response, immunogenicity or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0128] As used herein, the term “pharmaceutically acceptable salt” is intended to include all salts known and used in the art of pharmaceuticals. Pharmaceutically acceptable salts include, but are not limited to, amine salts, such as but not limited to chloroprocaine, choline, N,N’-dibenzyl-ethylenediamine, ammonia, diethanolamine and other hydroxy alkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzyl-phenethylamine, 1-para-chloro-benzyl-2-pyrrolidin-r-ylmethyl-benzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxy-methyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, such as but not limited to zinc; and other metal salts, such as but not limited to sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to, salts of mineral acids, such as but not limited to hydrochlorides and sulfates; and salts of organic acids, such as but not limited to acetates, lactates, malates, tartrates, citrates, ascorbates, succinates, butyrates, valerates and fumarates. Exemplary pharmaceutically acceptable salts include acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartrate, mesylate, borate, methylbromide, methylnitrate, calcium edetate, methylsulfate, camsylate, mucate, carbonate,napsylate, bromide, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estolate, palmitate, esylate, pantothenate, fumarate, phosphate / diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutamate, stearate, glycollylarsanilate, sulfate, hexylresorcinate, subacetate, hydrabamine, succinate, hydrobromide, tannate, hydrochloride, tartrate, hydroxynaphthoate, teoclate, iodide, tosylate, triethiodide, lactate, panoate and valerate, which can be used as a dosage form for modifying the solubility or hydrolysis characteristics or can be used in sustained release or pro-drug formulations. The preparation of the pharmaceutically acceptable salts described above and other typical pharmaceutically acceptable salts is more fully described by Berg et al., “Pharmaceutical Salts,” J. Pharm. Sci. 66: 1-19 (1977).

[0129] In certain embodiments, contemplated salts of the invention include, but are not limited to, L-arginine, benenthamine, benzathine, betaine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucamine, hydrabamine, IH-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, potassium, l-(2-hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine and zinc salts. In certain embodiments, contemplated salts of the invention include, but are not limited to, Na, Ca, K, Mg, Zn or other metal salts.

[0130] As used herein, the phrase “pharmaceutically acceptable carrier” or “excipient” refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients or carriers are generally safe, nontoxic and neither biologically nor otherwise undesirable and include excipients or carriers that are acceptable for veterinary use as well as human pharmaceutical use.

[0131] “Pharmaceutical composition” refers to a therapeutically active compound and at least one pharmaceutically acceptable carrier or excipient, with which the compound is administered to a patient.

[0132] The term “stereoisomers” refers to any enantiomers, diastereoisomers, or geometrical isomers, such as of the compounds of the invention. When compounds of the invention are chiral, they can exist in racemic or in optically active form. Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use compounds that are enriched in one of the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as suchin the synthesis. In the case of racemic amines, diastereomers are formed from the mixture by reaction with an optically active resolving agent. Examples of suitable resolving agents are optically active acids such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (for example N-benzoylproline or N-benzenesulfonylproline), or the various optically active camphorsulfonic acids. Also advantageous is chromatographic enantiomer resolution with the aid of an optically active resolving agent (for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel).

[0133] The term “ester”, as used herein, refers to a group -C(O)OR wherein R represents a hydrocarbyl group.

[0134] The term “amide”, as used herein, refers to a group -C(0)NH2.

[0135] As used herein, the term “comprise(s)” or “comprising” is generally used in the sense of include, that is to say permitting the presence of one or more additional (unspecified) features or components.

[0136] As used herein, the term “including” as well as other forms, such as “include”, “includes,” and “included,” is not limiting.

[0137] As used herein, the term “disease” or “disorder” refers to a pathological condition in an organism resulting from cause or condition including, but not limited to, infections, acquired conditions, genetic conditions, and characterized by identifiable symptoms. Diseases and disorders also include those that are caused by the absence of a compound.

[0138] The term “inhibitor” as used herein may include any molecule that partially or fully blocks, inhibits, suppresses, reduces, and / or neutralizes the expression of or the biological activity of a protein. The blocking, inhibiting, suppressing, reducing, and / or neutralizing of biological activity includes, but is not limited to, tumor growth or tumor secretory activity. The term “inhibitor” may also include any molecule that partially or fully blocks, inhibits, suppresses, reduces and / or neutralizes a biological activity of the CD47-SIRPa pathway. The term “CD47-SIRPa pathway inhibitor” or “CD47 pathway inhibitor” or “CD47 signalling pathway inhibitor” or “CD47-SIRPa signalling pathway inhibitor” as used herein may include any molecule that partially or fully blocks, inhibits, suppresses, reduces and / or neutralizes the signalling of the CD47 signalling pathway or partially or fully blocks, inhibits, suppresses,reduces and / or neutralizes a biological activity of one or more components of the CD47 signalling pathway.

[0139] The term “co-administering” or “administering simultaneously” as used herein with respect to the at least one additional therapeutic agent means that the at least one additional therapeutic agent may be administered together with compound of formula (I), or a pharmaceutically acceptable salt thereof, as part of a single dosage form (such as a composition comprising compound of formula (I), or a pharmaceutically acceptable salt thereof, and the at least one additional therapeutic agent) or as separate, multiple dosage forms. Alternatively, the at least one additional therapeutic agent may be administered prior to, consecutively with, or following the administration of compound of formula (I), or a pharmaceutically acceptable salt thereof. In such combination therapy treatment, both compound of formula (I), or a pharmaceutically acceptable salt thereof, and the at least one additional therapeutic agent are administered by conventional methods. The administration of a composition comprising both compound of formula (I), or a pharmaceutically acceptable salt thereof, and the at least one additional therapeutic agent, to a subject does not preclude the separate administration of that same therapeutic agent, any other additional therapeutic agent or any compound provided herein to said subject at another time during a course of treatment. The term “co- administering” or “administering simultaneously” as used herein with respect to an additional cancer treatment means that the additional cancer treatment may occur prior to, consecutively with, concurrently with or following the administration of a compound provided herein.

[0140] The term “sequentially administering” means that each dose is administered to the subject at a different point in time, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks or months). When both therapeutic agents are co-administered sequentially the therapeutic agents are administered in two separate administrations that are separated by a "specific period of time". The term specific period of time is meant anywhere from 1 hour to 120 days, preferably from 1 hour to 60 days, more preferably from 1 hour to 30 days. For example, one of the agents can be administered within about 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 day, or 24, 23,22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 hour from the administration of the other therapeutic agent, and, in one embodiment, the specific period time is 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 day, or 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5,4, 3, 2 or 1 hour.As used herein, “compound of formula (I)” may be alternatively referred to as “compound represented by formula (I)” or “formula (I)” or “compound 1” or “test compound”.

[0141] The synthetic procedure for the preparation of compound of formula (I) free acid as described in the present disclosure, is disclosed on page 54-59 international publication No. WO / 2019 / 138367 and the synthetic procedure for the preparation of compound of formula (I) calcium salt is disclosed on page 41-42 of international publication No. WO / 2025 / 083628.

[0142] In some embodiments, as disclosed herein, “a calcium salt thereof’ refers to the “calcium salt of compound of formula (I)”.

[0143] Pharmaceutical compositions

[0144] In some embodiments, the disclosure relates to a pharmaceutical composition comprising the compound of formula (I) or the calcium salt of compound of formula (I) in accordance with the disclosure and one or more pharmaceutically acceptable excipients for the treatment of neuroendocrine tumors.

[0145] In some embodiments, the present disclosure relates to a pharmaceutical composition comprising the compound of formula (I) or the calcium salt of compound of formula (I) in accordance with the disclosure in combination with at least one other therapeutic agent and a pharmaceutically acceptable carrier or excipient for the treatment of neuroendocrine tumors.

[0146] In some embodiments, the present disclosure provides a use of pharmaceutical composition comprising the compound of formula (I) or the calcium salt of compound of formula (I) as described herein and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent) for the treatment of neuroendocrine tumors.

[0147] The compounds described in the present disclosure are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the present disclosure. The pharmaceutical composition of the present disclosure comprises one or more compounds described herein and one or more pharmaceutically acceptable excipients. Typically, the pharmaceutically acceptable excipients are approved by regulatory authorities or are generally regarded as safe for human or animal use. The pharmaceutically acceptable excipients include, but are not limited to, carriers, diluents, glidants and lubricants, preservatives, buffering agents, chelating agents, polymers, gelling agents, viscosifying agents, solvents and the like.The pharmaceutical composition can be administered by oral, parenteral or inhalation routes. Examples of the parenteral administration include administration by injection, percutaneous, transmucosal, trans nasal and transpulmonary administrations.

[0148] Examples of suitable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, lactose, sucrose, dextrin, magnesium carbonate, sugar, amylose, magnesium stearate, talc, stearic acid, lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, fatty acid esters and polyoxyethylene.

[0149] The pharmaceutical composition may also include one or more pharmaceutically acceptable auxiliary agents, wetting agents, suspending agents, preserving agents, buffers, sweetening agents, flavouring agents, colorants or any combination of the foregoing.

[0150] The pharmaceutical compositions may be in conventional forms, for example, tablets, capsules, solutions, suspensions, injectables or products for topical application. Further, the pharmaceutical composition of the present disclosure may be formulated to provide desired release profile.

[0151] Administration of compounds of the disclosure, in pure form or in an appropriate pharmaceutical composition, can be carried out using any of the accepted routes of administration. The route of administration may be any route which effectively transports the compound of the present disclosure to the appropriate or desired site of action. Suitable routes of administration include, but are not limited to, oral, nasal, buccal, dermal, intradermal, transdermal, parenteral, rectal, subcutaneous, intravenous, intraurethral, intramuscular or topical.

[0152] Solid oral formulations include, but are not limited to, tablets, capsules (soft or hard gelatin), dragees (containing the active ingredient in powder or pellet form), troches and lozenges.

[0153] Liquid formulations include, but are not limited to, syrups, emulsions and sterile injectable liquids, such as suspensions or solutions.

[0154] Topical dosage forms of the compounds include ointments, pastes, creams, lotions, powders, solutions, eye or ear drops, impregnated dressings and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration.The pharmaceutical compositions of the present disclosure may be prepared by conventional techniques known in literature.

[0155] Features from different embodiments of the entire description may be freely combined with or supplement those previously described or permuted unless technically incompatible. These further provide basis for various levels of generalization or specification as may be required. It is further understood that variants, modifications, and equivalents of the features are also contemplated within the scope of the invention.

[0156] The various aspects and embodiments as defined in the foregoing will be further illustrated by means of the following non-limiting examples.

[0157] ABBREVIATIONS:

[0158] The abbreviations used in the entire specification is summarized below with their meaning. CT- Computed tomography; PET- Positron Emission Tomography; RECIST- Response Evaluation Criteria in Solid Tumors.

[0159] EXAMPLES

[0160] 1. Treatment of a NET with a CD47-SIRPa pathway inhibitor

[0161] In the first-in human, phase 1 , single agent dose escalation clinical trial, among the 27 solid tumor patients, it was surprisingly found that one of the patients had a diagnosis of neuroendocrine tumor. The patient was a 53-year-old female, who was diagnosed with a well differentiated Stage 4 neuroendocrine tumor (NET) with mid-gut origin (duodenal-jejunal region) about 6 years ago, at the age of 47 years.

[0162] Past medical history of the patient:

[0163] The patient had previously undergone a hysterectomy for an unknown gynecological reason. After hysterectomy, the patient had complaints of mild abdominal pain and repeated episodes of nausea and vomiting. The patient continued to have multiple scans and after 3 years, she was diagnosed with liver lesions. Biopsy and work up revealed well-differentiated NET of small intestinal origin. Initial treatment was palliative chemotherapy with Paclitaxel (5-6 cycles) followed by oral Gefitinib. Follow up evaluations and CT scans were performed for four consecutive years. The disease was found to be stable (as per RECIST 1.1 criteria) all these years. During 4thyear, the patient was administered with a few cycles of the Cabazitaxel.Follow up evaluations and CT scans were performed subsequently. The disease was found to be stable (as per RECIST 1.1 criteria) during these evaluations.

[0164] Treatment with test compound (compound of formula (I)):

[0165] The patient was enrolled in the clinical trial and was assigned to the 200 mg BID dose of compound of formula (I) (cohort 4).

[0166] Figure 1 provides the PET-CT scan image of abdominal lesion in peritoneum before (baseline) and after (at Cycle 6) the administration of the test compound (compound of formula (I)). By referring to figure 1 , it can be observed that there was a marked decrease in the diameter of the abdominal lesion at cycle 6 (20.3 mm) of the administration of test compound (compound of formula (I)), compared to baseline (32.6 mm).

[0167] Figure 2 provides the PET-CT scan image of the first metastatic lesion in left lobe of liver before (baseline) and after (at Cycle 6) administration of the test compound (compound of formula (I)). By referring to figure 2, it can be observed that there was a marked decrease in the diameter of the first metastatic lesion in left lobe of liver at cycle 6 (41.3 mm) of the administration of test compound (compound of formula (I)), compared to baseline (54.3 mm).

[0168] Figure 3 provides the PET-CT scan image of the second metastatic lesion in left lobe of liver before (baseline) and after (at Cycle 6) the administration of the test compound (compound of formula (I)). By referring to figure 3, it can be observed that there was a marked decrease in the diameter of the second metastatic lesion in left lobe of liver at cycle 6 (17.7 mm) of the administration of test compound (compound of formula (I)), compared to baseline (31.7 mm).

[0169] As observed herein, the treatment of NET using the compound of formula (I) is clinically significant, as a consistent decrease in the tumor size can be observed.

[0170] Efficacy assessment of the compound of formula (I) by CT scan imaging:

[0171] As per the study protocol, the CT scan imaging was performed every two cycles and the details regarding the response as per the RECIST 1.1 criteria are shown in table- 1 below.

[0172] Table-1:

[0173] Treatment Screening Cycle 2 (2ndCycle 4 (4thCycle 6 Cycle 8 (7thCycles (Month zero) month) month) (6thmonth) month) Target lesion size 118.8 mm 108.9 mm 109.8 mm 79.3 mm 80 mm

[0174]

[0175] % change from -- -8.33% -7.5% -33.24% -32.66% baseline

[0176] Response Stable Stable Partial Confirmed Disease Disease response Partial response Target Lesion: 1) Liver: SUV 1) Liver: 1) Liver: 1) Liver: 1 ) Liver: SUV 6.6 SUV 7.2 SUV 6.3 SUV 5.6 SUV 3.2

[0177] 2) Liver: SUV 2) Liver: 2) Liver: 2) Liver: 2) Liver: 7.9 SUV 8.3 SUV 10.5 SUV 6.9 SUV 4.8 3) Abdomen: 3) Abdomen: 3) 3) 3)

[0178] SUV 3.5 SUV 5.1 Abdomen: Abdomen: Abdomen:

[0179] SUV 5.1 SUV 3.9 SUV 2.9

[0180]

[0181] [(-) sign indicates decrease in the size of target lesions]

[0182] By referring to Table- 1, it can be observed that the cycle 6 scans showed a partial response, which was further confirmed at cycle 8. In alignment with the RECIST criteria, there was a sustained decrease in the Standardized Uptake Value (SUV) of the target lesions from cycle 6 onwards, and this was maintained at cycle 8.

[0183] Safety summary:

[0184] The patient experienced a total of two adverse events, namely, dyspnea and hyperacidity. Both the adverse events were mild in severity and were managed symptomatically and were eventually resolved. As per the causality assessment, both the adverse events were termed as ‘Not related’ to the test compound.

[0185] Incorporation by Reference:

[0186] All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

[0187] Equivalents:

[0188] While specific embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the disclosure will become apparent to those skilled in the art upon review of this specification and the claims below. Thefull scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents and the specification, along with such variations.

Claims

We claim:

1. A method for treating neuroendocrine tumor (NET) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a CD47- SIRPa pathway inhibitor.

2. The method of claim 1, wherein the CD47-SIRPa pathway inhibitor is selected from the group consisting of a small molecule inhibitor and an anti-CD47 antibody.

3. The method of claim 2, wherein the anti-CD47 antibody is selected from the group consisting of a polyclonal antibody, a recombinant antibody, a monoclonal antibody, an antibody fragment, a single-chain variable fragment (scFv), a chimeric antibody, a humanized antibody, and a fusion protein.

4. The method of claim 2, wherein the CD47-SIRPa pathway inhibitor is selected from the group consisting of evorpacept, ligufalimab, letaplimab, lemzoparlimab, magrolimab, maplirpacept, simridarlimab, ISM-8207, TQB-2928, XL-114, IMC-002, STI-6643, HMPL-A83, DS-1103, SG-2501, IMM-02, IMM-4002, IMM-6101, CO-005, IMD-1005, ALTA-002, CC-90002, MP 0621, VT-1021, AO-176, DSP-107, JMT-601, TTI-621, IMM- 2902, ISB-1442, HX-009, 6MW-3211, SG-404, GenSci-05, SHR-1603, MIL-95, NI-1801, SG-1906, AK-132, IMM-2520, SG-12473, SHS-009, BAT-7104, QL-401, D3L-001, BC- 007, TG-1801, AVI-105, KD-015, SCR-9168, HX-015, GB-7005, FP-002, SY-102, LP- 007, DS-003, LQ-001, SBI-102, KBI-436, TRB-805-01, IMM-5601 and SC-2882.

5. The method of claim 2, wherein the CD47-SIRPa pathway inhibitor is selected from the group consisting of evorpacept, letaplimab, magrolimab, ISM-8207, TQB-2928, XL-114, IMC-002, STI-6643, HMPL-A83, DS-1103, SG-2501, IMM-02, IMM-4002, IMM-6101, CO-005, IMD-1005, ALTA-002, CC-90002, MP 0621 and SC-2882.

6. The method of claim 2, wherein the CD47-SIRPa pathway inhibitor is selected from the group consisting of evorpacept, letaplimab, magrolimab and STI-6643.

7. The method of claim 1, wherein the CD47-SIRPa pathway inhibitor is a compound of formula (I):or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof.

8. The method of claim 7, wherein the CD47-SIRPa pathway inhibitor is a calcium salt of the compound of formula (I).

9. The method of claim 1, wherein the subject is a human.

10. The method of claim 1, wherein the neuroendocrine tumor is a low grade, medium grade or high-grade neuroendocrine tumor.

11. The method of claim 1 , wherein the neuroendocrine tumor is a functional neuroendocrine tumor or a non-functional neuroendocrine tumor.

12. The method of claim 1, wherein the neuroendocrine tumor is a poorly differentiated neuroendocrine tumor or a well-differentiated neuroendocrine tumor.

13. The method of claim 1, wherein the neuroendocrine tumor is an advanced or metastatic neuroendocrine tumor, or a combination thereof.

14. The method of claim 1, wherein the neuroendocrine tumor is selected from the group consisting of lung neuroendocrine tumor, bronchial neuroendocrine tumor, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumors, gastroenteropancreatic neuroendocrine tumor, small intestine neuroendocrine tumor, large intestine neuroendocrine tumor, rectal neuroendocrine tumor, appendix neuroendocrine tumor, duodenal-jejunal neuroendocrine tumor, ovarian neuroendocrine tumor, pheochromocytomas, paragangliomas, medullary thyroid cancer, metastatic neuroendocrine tumor, thymic neuroendocrine tumor, pituitary neuroendocrine tumor, Merkel-cell carcinoma, Ewing's sarcoma, rectal neuroendocrine tumors, duodenalneuroendocrine tumor, jejunal neuroendocrine tumor, neuroendocrine tumor of the ileum and neuroblastoma, or any combination thereof.

15. The method of claim 14, wherein the neuroendocrine tumor is selected from the group consisting of lung neuroendocrine tumor, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumors, and gastroenteropancreatic neuroendocrine tumor, or any combination thereof.

16. The method according to any one of claim 1-15, wherein the compound of formula (I) or a calcium salt thereof is administered to the subject via an oral route.

17. The method according to any one of claim 1-16, wherein the compound of formula (I) or a calcium salt thereof is administered to the subject once or twice daily.

18. The method according to any one of claim 1-17, wherein the compound of formula (I) or calcium salt thereof is administered at a total daily dose not exceeding 800 mg, preferably not exceeding 600 mg, more preferably not exceeding 500 mg, most preferably not exceeding 400 mg.

19. The method of any one of the claims is 1 to 18, wherein the subject receives at least one additional form of therapy.

20. The method of claim 19, wherein the additional form of therapy is selected from surgery, combination therapy, chemotherapy, and radiation therapy.

21. The method of any one of the claims is 1 to 20, further comprising administering to the subject a therapeutically effective amount of an additional therapeutic agent.

22. The method of claim 21, wherein the additional therapeutic agent is selected from the group consisting of everolimus, sunitinib, cabozantinib, and somatostatin analogs.

23. A method for suppressing secretory activity of neuroendocrine tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a CD47-SIRPa pathway inhibitor.

24. The method of claim 23, wherein the CD47-SIRPa pathway inhibitor is a compound of formula (I):or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof.

25. The method of claim 24, wherein the CD47-SIRPa pathway inhibitor is a calcium salt of the compound of formula (I).

26. Use of a CD47-SIRPa pathway inhibitor of formula (I), or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof, in the manufacture of a medicament for treating neuroendocrine tumor in a subject:(I)27. Use of claim 26, wherein the neuroendocrine tumor is selected from the group consisting of lung neuroendocrine tumor, bronchial neuroendocrine tumor, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumors, gastroenteropancreatic neuroendocrine tumor, small intestine neuroendocrine tumor, large intestine neuroendocrine tumor, rectal neuroendocrine tumor, appendix neuroendocrine tumor, duodenal-jejunal neuroendocrine tumor, ovarian neuroendocrine tumor, pheochromocytomas, paragangliomas, medullary thyroid cancer, metastatic neuroendocrine tumor, thymic neuroendocrine tumor, pituitary neuroendocrine tumor, Merkel-cell carcinoma, Ewing's sarcoma, rectalneuroendocrine tumors, duodenal neuroendocrine tumor, jejunal neuroendocrine tumor, neuroendocrine tumor of the ileum and neuroblastoma or any combination thereof.

28. Use of claim 27, wherein the neuroendocrine tumor is selected from the group consisting of lung neuroendocrine tumor, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumors and gastroenteropancreatic neuroendocrine tumor or any combination thereof.

29. A CD47-SIRPa pathway inhibitor for use in treating neuroendocrine tumor in a subject in need thereof.

30. The CD47-SIRPa pathway inhibitor for use of claim 29, wherein the inhibitor is a compound of formula (I):OH HNXNl2N A NHor a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof.

31. The CD47-SIRPa pathway inhibitor for use of claim 29 or 30, wherein the inhibitor is a calcium salt of the compound of formula (I).

32. The CD47-SIRPa pathway inhibitor for use of any of the claims 29 to 31, wherein the neuroendocrine tumor is selected from the group consisting of lung neuroendocrine tumor, bronchial neuroendocrine tumor, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumors, gastroenteropancreatic neuroendocrine tumor, small intestine neuroendocrine tumor, large intestine neuroendocrine tumor, rectal neuroendocrine tumor, appendix neuroendocrine tumor, ovarian neuroendocrine tumor, pheochromocytomas, paragangliomas, medullary thyroid cancer, metastatic neuroendocrine tumor, thymic neuroendocrine tumor, pituitary neuroendocrine tumor, Merkel-cell carcinoma, Ewing's sarcoma, rectal neuroendocrine tumors, duodenal neuroendocrine tumor, jejunalneuroendocrine tumor, neuroendocrine tumor of the ileum and neuroblastoma, or any combination thereof.

33. The CD47-SIRPa pathway inhibitor for use of any of the claims 29 to 31, wherein the neuroendocrine tumor is selected from the group consisting of lung neuroendocrine tumor, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumors and gastroenteropancreatic neuroendocrine tumor, or any combination thereof.

34. A pharmaceutical composition comprising a compound of formula (I) or a calcium salt thereof, and one or more pharmaceutically acceptable excipients, for use in the treatment of neuroendocrine tumor selected from the group consisting of lung neuroendocrine tumor, pancreatic neuroendocrine tumor, gastrointestinal neuroendocrine tumors and gastroenteropancreatic neuroendocrine tumor, or any combination thereof.